|
|
 |
|
Viewing report
|
|
|
|
Autoimmune Disease Therapeutics
Greystone Associates, Aug 2008, Pages: 130
As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape
Market Data
The study presents qualitative and quantitative data and information on key market measures and benchmarks:
- Autoimmune Target Activity
- Development-stage Candidate Assessment
- Therapeutic Segment Data
- Market Projections by Therapy
- Industry Structure & Competitive Landscape
- Emerging Therapies Opportunity/Risk Assessment
- US/EU Regulatory Climate
- Commercialization Factors
- Technology Factors
- Projections to 2011
Feature Summary
- Analyzes and evaluates emerging therapeutic candidates for autoimmune diseases and assesses their commercial potential
- Assesses existing and evolving immune cascade disease models and treatment protocol factors
- Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific development stage candidates
- Evaluates the global opportunity for autoimmune therapeutics
- Provides market data and forecasts for six major autoimmune disease segments
- Profiles market participants, their technology, products, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on autoimmune therapeutics commercialization
Customers who bought this item also bought
Autoimmune Disease Therapeutics - Global Strategic Business Report
Autoimmune Market Outlook to 2012
Autoimmune Treatment (2009 - 2014)
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
What Strategies Will Yield Novel Treatments for Autoimmune Disease?
European Autoimmune Disease Diagnostics Market
European Autoimmune Diseases Therapeutics Markets
Autoimmune Disease Series: Systemic Sclerosis--Novel Treatment Approaches on the Horizon
The Autoimmune Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Commercial Insight: Autoimmune Overview - Market continues to prosper
Physician Perception of Biologics in Autoimmune Disease - Targeted Detailing is the Key to Success
Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?
|
|
|
|
